These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3821428)

  • 21. [Drug-eruptions].
    Thielen AM; Toutous-Trellu L; Desmeules J
    Rev Med Suisse; 2008 Jul; 4(165):1671-5. PubMed ID: 18767294
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The safety of drugs].
    de Cea Lavech de Chancy H
    Rev Clin Esp; 1990 Sep; 187(4):184-90. PubMed ID: 2091076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Regulatory guidelines and drug safety].
    Flury W
    Ther Umsch; 1993 Jan; 50(1):49-51. PubMed ID: 8378867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug related hospital admissions in subspecialities of internal medicine.
    Hallas J
    Dan Med Bull; 1996 Apr; 43(2):141-55. PubMed ID: 8741207
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the post-marketing authorisation studies in drug risk surveillance: specifications and methodologies.
    Tubach F; Lamarque-Garnier V; Castot A;
    Therapie; 2011; 66(4):355-62, 347-54. PubMed ID: 21851800
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 28. The management of adverse drug reactions: from diagnosis to signal.
    Edwards IR
    Therapie; 2001; 56(6):727-33. PubMed ID: 11878098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Communicating the risks and benefits of medicines.
    Schmid EF; Smith DA; Ryder SW
    Drug Discov Today; 2007 May; 12(9-10):355-64. PubMed ID: 17467571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 31. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 32. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 33. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 34. A call for international harmonization in therapeutic risk management.
    Hirst C; Cook S; Dai W; Perez-Gutthann S; Andrews E
    Pharmacoepidemiol Drug Saf; 2006 Dec; 15(12):839-49; discussion 850-1. PubMed ID: 16981215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Building a structured monitoring and evaluating system of postmarketing drug use in Shanghai.
    Du W; Levine M; Wang L; Zhang Y; Yi C; Wang H; Wang X; Xie H; Xu J; Jin H; Wang T; Huang G; Wu Y
    Can J Clin Pharmacol; 2007; 14(1):e40-4. PubMed ID: 17237524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval.
    Borer JS; Pouleur H; Abadie E; Follath F; Wittes J; Pfeffer MA; Pitt B; Zannad F
    Eur Heart J; 2007 Aug; 28(15):1904-9. PubMed ID: 17615083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of backgrounds in safety analysis: the impact of comparison cases on what you see.
    Gogolak VV
    Pharmacoepidemiol Drug Saf; 2003; 12(3):249-52. PubMed ID: 12733479
    [No Abstract]   [Full Text] [Related]  

  • 40. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.